BioLife Solutions Makes Strategic Investment in Pluristyx
BioLife Solutions (NASDAQ: BLFS), a leading bioproduction products supplier for cell and gene therapy, has made a $2 million strategic investment in Pluristyx through convertible notes. The investment includes a board observer seat and potential future acquisition rights.
Pluristyx, a Seattle-based company, develops innovative induced pluripotent stem cell (iPSC) products for cell therapy developers. The investment aligns with BioLife's strategy of exploring biological assays as a product portfolio expansion, following similar investments in Sexton and PanTHERA.
BioLife Solutions (NASDAQ: BLFS), un fornitore leader di prodotti per la bioproduzione nel campo della terapia cellulare e genica, ha effettuato un investimento strategico di 2 milioni di dollari in Pluristyx tramite note convertibili. L'investimento prevede un posto come osservatore nel consiglio di amministrazione e potenziali diritti di acquisizione futuri.
Pluristyx, azienda con sede a Seattle, sviluppa prodotti innovativi a base di cellule staminali pluripotenti indotte (iPSC) per sviluppatori di terapie cellulari. L'investimento è in linea con la strategia di BioLife di esplorare saggi biologici come espansione del portafoglio prodotti, seguendo investimenti simili in Sexton e PanTHERA.
BioLife Solutions (NASDAQ: BLFS), un proveedor líder de productos para bioproducción en terapias celulares y génicas, ha realizado una inversión estratégica de 2 millones de dólares en Pluristyx mediante notas convertibles. La inversión incluye un asiento como observador en la junta directiva y posibles derechos futuros de adquisición.
Pluristyx, una empresa con sede en Seattle, desarrolla productos innovadores de células madre pluripotentes inducidas (iPSC) para desarrolladores de terapias celulares. La inversión se alinea con la estrategia de BioLife de explorar ensayos biológicos como expansión de su portafolio de productos, tras inversiones similares en Sexton y PanTHERA.
BioLife Solutions (NASDAQ: BLFS)는 세포 및 유전자 치료를 위한 바이오생산 제품의 선도 공급업체로서, 전환사채를 통해 Pluristyx에 200만 달러의 전략적 투자를 진행했습니다. 이번 투자는 이사회 옵서버 자리와 향후 인수 권리 가능성을 포함합니다.
시애틀에 본사를 둔 Pluristyx는 세포 치료 개발자를 위한 혁신적인 유도 만능 줄기세포(iPSC) 제품을 개발하고 있습니다. 이번 투자는 BioLife가 Sexton과 PanTHERA에 대한 유사한 투자를 이어가며 생물학적 분석법을 제품 포트폴리오 확장의 일환으로 탐색하는 전략과 부합합니다.
BioLife Solutions (NASDAQ: BLFS), un fournisseur leader de produits de bioproduction pour la thérapie cellulaire et génique, a réalisé un investissement stratégique de 2 millions de dollars dans Pluristyx via des billets convertibles. Cet investissement inclut un siège d’observateur au conseil d’administration ainsi que des droits potentiels d’acquisition futurs.
Pluristyx, une entreprise basée à Seattle, développe des produits innovants à base de cellules souches pluripotentes induites (iPSC) pour les développeurs de thérapies cellulaires. Cet investissement s’inscrit dans la stratégie de BioLife d’explorer les tests biologiques comme extension de son portefeuille de produits, à l’instar d’investissements similaires réalisés dans Sexton et PanTHERA.
BioLife Solutions (NASDAQ: BLFS), ein führender Anbieter von Bioproduktionsprodukten für Zell- und Gentherapie, hat eine strategische Investition von 2 Millionen US-Dollar in Pluristyx durch wandelbare Schuldverschreibungen getätigt. Die Investition umfasst einen Sitz als Beobachter im Vorstand sowie potenzielle zukünftige Übernahmerechte.
Pluristyx, ein Unternehmen mit Sitz in Seattle, entwickelt innovative Produkte aus induzierten pluripotenten Stammzellen (iPSC) für Entwickler von Zelltherapien. Die Investition entspricht der Strategie von BioLife, biologische Tests als Erweiterung des Produktportfolios zu erkunden, ähnlich wie bei früheren Investitionen in Sexton und PanTHERA.
- Strategic $2 million investment expands BioLife's presence in cell therapy market
- Secured board observer seat and potential acquisition rights in Pluristyx
- Investment aligns with company's portfolio expansion strategy in biological assays
- Builds on existing collaboration between the companies
- Investment amount is relatively small compared to typical industry transactions
- Return on investment timeline and potential returns are uncertain
Roderick de Greef, BioLife's Chairman and CEO, remarked, "We have known and worked with the founding team at Pluristyx for many years, and have a great deal of respect for their scientific expertise in cell therapy. Their recent development of an iPSC-based biological assay for organoid manufacturing dovetails with our interest in exploring biological assays more broadly as a product portfolio adjacency. This strategic investment follows the same playbook as those we made in Sexton and PanTHERA and is a logical continuation of the recent collaboration between our two companies."
Benjamin Fryer, PhD, Pluristyx's CEO, commented, "It is gratifying to have BioLife Solutions validate our vision with its investment. Their support will allow us to manufacture, commercialize and distribute our innovative solutions and help our customers solve critical industry challenges."
About Pluristyx
Pluristyx is dedicated to enabling the development of next-generation cell-based tools and therapies. PluriKit™, PluriForm™ Organoids, and PluriBank™ stem cells incorporating safety and tolerance features like FailSafe®, iACT™, and hypoimmune engineering streamline developers' path to the clinic and approval. Pluristyx's iPSC lines, backed by an FDA registered drug master file, with platform genetic engineering are available "off-the-shelf" along with comprehensive support services to accelerate the creation of novel diagnostics, screening and safety testing, and curative treatments. For more information, visit www.pluristyx.com.
About BioLife Solutions
BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage, and distribution. For more information, please visit www.biolifesolutions.com or follow BioLife on LinkedIn and X.
Cautions Regarding Forward Looking Statements
Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans," "expects," "believes," "anticipates," "designed," and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the
Media & Investor Relations
At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400
twichterman@biolifesolutions.com
Investors
Alliance Advisors IR
Jody Cain
(310) 691-7100
jcain@allianceadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-makes-strategic-investment-in-pluristyx-302514454.html
SOURCE BioLife Solutions, Inc.
FAQ
How much did BioLife Solutions (BLFS) invest in Pluristyx?
What rights did BioLife Solutions (BLFS) receive in the Pluristyx investment?
Why did BioLife Solutions (BLFS) invest in Pluristyx?
What does Pluristyx develop?
How does the Pluristyx investment fit into BioLife Solutions' strategy?
